文献速递肿瘤 PET/CT核素与放射性配体治疗

以PSMA-PET/CT分期为主的转移性前列腺癌原发定向放疗后的结局

Outcome after primary directed radiotherapy in predominantly PSMA-PET/CT-staged patients with metastatic prostate cancer.
PubMed 文献 · EJNMMI Res · 2026-06-23

中位随访40个月,中位无进展生存期(PFS)为80个月,中位总生存期(OS)未达到;低转移负荷(p=0.007)和同时性转移(p=0.027)预测更长的PFS。PDT联合转移灶定向治疗(MDT)和雄激素剥夺治疗(ADT)取得有前景的长期结局且毒性可接受。

要点

  • 中位PFS为80个月,3年PFS、bPFS和OS分别为78%、81%和84%。
  • 低转移负荷(p=0.007)和同时性转移(p=0.027)预测更长的PFS。
  • 无急性3级毒性;晚期3级胃肠道和泌尿生殖道毒性各占8%。

核心结论

  • 在以PSMA-PET/CT分期为主的队列中,PDT联合MDT和ADT取得有前景的长期结局且毒性可接受,需更大前瞻性研究确认。

主要发现

  • 中位PFS和bPFS分别为80和73个月,中位OS未达到;3年PFS、bPFS和OS分别为78%、81%和84%。
  • 低转移负荷(p=0.007)和同时性转移(p=0.027)预测更长的PFS。
  • 无急性3级毒性发生;晚期3级胃肠道和泌尿生殖道毒性各占8%。

关键数值与推荐

  • 最常见放疗方案为60 Gy分20次。
  • 23例接受ADT,其中6例联合雄激素受体信号抑制剂(中位持续时间23个月)。
  • 22例接受MDT,5例接受选择性淋巴结放疗。

临床怎么用

  • 对经PSMA-PET/CT分期为主的OMPC患者,可考虑PDT联合MDT和ADT,但需注意晚期3级胃肠道和泌尿生殖道毒性各8%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oligometastatic prostate cancer (OMPC) is typically treated with systemic therapy, which may be complemented by radiotherapy (RT) of the prostate as part of primary directed therapy (PDT). This study retrospectively evaluated clinical outcomes following PDT in OMPC. RESULTS: Twenty-four consecutive patients who underwent PDT for OMPC between 2011 and 2023 were analyzed retrospectively. The primary endpoint was progression-free survival (PFS); secondary endpoints included biochemical PFS (bPFS), overall survival (OS), and treatment-related toxicity. Survival was estimated using Kaplan-Meier analysis, and prognostic factors for PFS were assessed using univariate log-rank tests and multivariate Cox regression. The median follow-up was 40 months. Median age was 75 years (range: 58-83), with a median of two metastases (range: 1-5). Nineteen patients (79%) were staged with PSMA-PET/CT; 20 had synchronous and 20 low-burden disease (CHAARTED criteria). The most common RT regimen was 60 Gy in 20 fractions. Twenty-three patients received androgen deprivation therapy (ADT), including six with an androgen receptor signaling inhibitor (median duration: 23 months). Additionally, 22 underwent metastasis-directed therapy (MDT), and five elective nodal RT. Median PFS and bPFS were 80 and 73 months, respectively; median OS was not reached. Three-year PFS, bPFS, and OS were 78%, 81%, and 84%. Low metastatic burden (p = 0.007) and synchronous metastases (p = 0.027) predicted longer PFS. No acute grade 3 toxicity occurred; late grade 3 gastrointestinal and genitourinary toxicity occurred in 8% each. CONCLUSIONS: In this predominantly PSMA-PET/CT-staged cohort, PDT combined with MDT and ADT achieved promising long-term outcomes with acceptable toxicity, warranting confirmation in larger prospective studies.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Trapp C, Brose SF, Keilholz M, et al. Outcome after primary directed radiotherapy in predominantly PSMA-PET/CT-staged patients with metastatic prostate cancer. EJNMMI Res. 2026. PMID: 42334759. doi:10.1186/s13550-026-01473-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。